Andrea Iannaccone1, G Bruno2, A Ravera2, F Gay3, M Salvini3, S Bringhen3, L Sabia2, E Avenatti2, F Veglio2, A Milan2. 1. Hypertension Unit, Division of Internal Medicine, Department of Medical Sciences, University Hospital "Città della Salute e della Scienza", University of Torino, Turin, Italy. iannaccone.andrea@gmail.com. 2. Hypertension Unit, Division of Internal Medicine, Department of Medical Sciences, University Hospital "Città della Salute e della Scienza", University of Torino, Turin, Italy. 3. Myeloma Unit, Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University Hospital 'Città della Salute e della Scienza di Torino', University of Torino, Turin, Italy.
Abstract
INTRODUCTION: Recently new treatment options have substantially increased survival for patients with relapsed and/or refractory multiple myeloma (RRMM). Among these, proteasome inhibitors (PI), such as bortezomib and carfilzomib, offer high response rate and prolonged survival. These agents are generally well tolerated but demonstrated a significant cardiovascular toxicity, mostly for regimen containing carfilzomib. AIM: To assess the cardiovascular damage in patients treated with PI for RRMM. METHODS: 28 consecutive subjects treated with PI for RRMM were evaluated and compared with a population of 22 control (Con) subjects, matched for age, sex and mean 24 h blood pressure (24hMBP). All individuals underwent trans-thoracic echocardiography, ambulatory blood pressure monitoring and pulse wave velocity (PVW) study. RESULTS: PI patients did not have significant differences in blood pressure load and PWV compared to controls. Among echocardiographic parameters, the global longitudinal strain (GLS) was significantly decreased in PI subjects (p = 0.02). The GLS was significantly lower also considering only patients treated with carfilzomib. Moreover, among carfilzomib patients, we found increase values of left ventricle mass indexed by BSA (LVMi; p = 0.047). After correction for age, sex, BSA, 24hMBP and morphological and functional parameters of LV, treatment with PI and carfilzomib were significantly associated with GLS (p = 0.01; p = 0.036, respectively). CONCLUSIONS: PI treatment is associated with subclinical LV dysfunction in patients with RRMM compared to controls, as demonstrated by lower GLS values. These results are confirmed also considering patients treated with carfilzomib. Moreover, in this subgroup of patients, the LVMi is also increased, suggesting higher cardiotoxicity with this treatment.
INTRODUCTION: Recently new treatment options have substantially increased survival for patients with relapsed and/or refractory multiple myeloma (RRMM). Among these, proteasome inhibitors (PI), such as bortezomib and carfilzomib, offer high response rate and prolonged survival. These agents are generally well tolerated but demonstrated a significant cardiovascular toxicity, mostly for regimen containing carfilzomib. AIM: To assess the cardiovascular damage in patients treated with PI for RRMM. METHODS: 28 consecutive subjects treated with PI for RRMM were evaluated and compared with a population of 22 control (Con) subjects, matched for age, sex and mean 24 h blood pressure (24hMBP). All individuals underwent trans-thoracic echocardiography, ambulatory blood pressure monitoring and pulse wave velocity (PVW) study. RESULTS: PI patients did not have significant differences in blood pressure load and PWV compared to controls. Among echocardiographic parameters, the global longitudinal strain (GLS) was significantly decreased in PI subjects (p = 0.02). The GLS was significantly lower also considering only patients treated with carfilzomib. Moreover, among carfilzomibpatients, we found increase values of left ventricle mass indexed by BSA (LVMi; p = 0.047). After correction for age, sex, BSA, 24hMBP and morphological and functional parameters of LV, treatment with PI and carfilzomib were significantly associated with GLS (p = 0.01; p = 0.036, respectively). CONCLUSIONS: PI treatment is associated with subclinical LV dysfunction in patients with RRMM compared to controls, as demonstrated by lower GLS values. These results are confirmed also considering patients treated with carfilzomib. Moreover, in this subgroup of patients, the LVMi is also increased, suggesting higher cardiotoxicity with this treatment.
Authors: Dermot Phelan; Patrick Collier; Paaladinesh Thavendiranathan; Zoran B Popović; Mazen Hanna; Juan Carlos Plana; Thomas H Marwick; James D Thomas Journal: Heart Date: 2012-08-03 Impact factor: 5.994
Authors: M S Ewer; M K Ali; B Mackay; S Wallace; M Valdivieso; S S Legha; R S Benjamin; T P Haynie Journal: J Clin Oncol Date: 1984-02 Impact factor: 44.544
Authors: Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng Journal: Lancet Oncol Date: 2015-12-05 Impact factor: 41.316
Authors: Lori Minasian; Eileen Dimond; Myrtle Davis; Bishow Adhikari; Richard Fagerstrom; Carol Fabian; Justin Floyd; Joseph M Unger; Pamela S Douglas; Karen M Mustian; Eric J Chow; Steven Lipshultz; W Gregory Hundley; Saro Armenian; Bonnie Ky Journal: JACC CardioOncol Date: 2019-09-24
Authors: Giulia Mingrone; Anna Astarita; Lorenzo Airale; Ilaria Maffei; Marco Cesareo; Teresa Crea; Giulia Bruno; Dario Leone; Eleonora Avenatti; Cinzia Catarinella; Marco Salvini; Giusy Cetani; Francesca Gay; Sara Bringhen; Franco Veglio; Fabrizio Vallelonga; Alberto Milan Journal: Front Cardiovasc Med Date: 2021-04-21
Authors: Michael A Biersmith; Matthew S Tong; Avirup Guha; Orlando P Simonetti; Daniel Addison Journal: J Am Heart Assoc Date: 2020-01-21 Impact factor: 5.501